Winton Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.15M | Buy |
+3,533
| New | +$1.15M | 0.06% | 384 |
|
|
2024
Q2 | – | Sell |
-1,471
| Closed | -$220K | – | 569 |
|
|
2024
Q1 | $220K | Buy |
+1,471
| New | +$220K | 0.02% | 550 |
|
|
2023
Q2 | – | Sell |
-3,425
| Closed | -$686K | – | 769 |
|
|
2023
Q1 | $686K | Buy |
+3,425
| New | +$686K | 0.04% | 572 |
|
|
2022
Q2 | – | Sell |
-3,046
| Closed | -$497K | – | 936 |
|
|
2022
Q1 | $497K | Buy |
+3,046
| New | +$497K | 0.03% | 683 |
|
|
2021
Q4 | – | Sell |
-2,911
| Closed | -$550K | – | 1004 |
|
|
2021
Q3 | $550K | Buy |
+2,911
| New | +$550K | 0.03% | 815 |
|
|
2020
Q4 | – | Sell |
-8,298
| Closed | -$1.21M | – | 1311 |
|
|
2020
Q3 | $1.21M | Sell |
8,298
-26,472
| -76% | -$3.85M | 0.04% | 734 |
|
|
2020
Q2 | $5.15M | Buy |
34,770
+25,785
| +287% | +$3.82M | 0.13% | 200 |
|
|
2020
Q1 | $978K | Buy |
+8,985
| New | +$978K | 0.03% | 810 |
|
|
2017
Q4 | – | Sell |
-90,504
| Closed | -$10.6M | – | 662 |
|
|
2017
Q3 | $10.6M | Buy |
+90,504
| New | +$10.6M | 0.34% | 76 |
|